Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

NCT07102394 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

NF1
Neurofibromatosis
Cutaneous Neurofibroma
Neurofibroma
Von Recklinghausen Disease
Neurofibromas

Interventions

DRUG: Imlygic

Sponsor

Johns Hopkins University

Collaborators

[object Object]